FORT MYERS — Cancer-testing firm NeoGenomics posted sales growth of 9% in the fourth quarter on the heels of its acquisition of rival Clarient from GE Healthcare Life Services.
Continue reading your article with a Business Observer subscription.
What's included:
✓ Unlimited digital access to BusinessObserverFL.com
✓ E-Newspaper app, digital replica of print edition